Tvardi Therapeutics, Inc. Logo

Tvardi Therapeutics, Inc.

Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.

TVRD | IL

Overview

Corporate Details

ISIN(s):
US1407553072 (+1 more)
LEI:
549300COVOY41P0GZ881
Country:
United States of America
Address:
3 SUGAR CREEK CTR. BLVD., 77478 SUGAR LAND
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies. The company's core technology targets STAT3 (Signal Transducer and Activator of Transcription 3), a key regulatory protein implicated in the progression of various diseases. Tvardi is advancing a pipeline of STAT3 inhibitors to treat conditions with significant unmet medical needs, primarily focusing on fibrosis-driven diseases and diverse cancers.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Tvardi Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Tvardi Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Tvardi Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
FRACTYL HEALTH, INC. Logo
Developing gut-targeted endoscopic and gene therapies for obesity and type 2 diabetes.
United States of America GUTS
Friulchem Logo
CDMO for animal health, providing vet pharma & supplement solutions for pets and livestock.
Italy FCM
Fuji Pharma Co.,Ltd. Logo
Specializes in hormone medicines for ob/gyn, injectables, and contract manufacturing.
Japan 4554
Fulcrum Therapeutics, Inc. Logo
Develops gene-modulating small molecule drugs for rare, genetically defined diseases.
United States of America FULC
Fuso Pharmaceutical Industries,Ltd. Logo
Manufactures essential pharmaceuticals like dialysis drugs, infusions, and injections for healthcare.
Japan 4538
FutureChem Co., Ltd. Logo
Develops radiopharmaceuticals & diagnostic agents for cancer, Alzheimer's, and Parkinson's disease.
South Korea 220100
Future Medicine  Co., Ltd. Logo
Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.
South Korea 341170
Develops long-acting injectable therapies for chronic diseases and cancer.
South Korea 456160
Gabather AB Logo
Developing novel GABAA receptor drugs for neuropsychiatric disorders.
Sweden GABA
Galapagos NV Logo
Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.
Belgium GLPG

Talk to a Data Expert

Have a question? We'll get back to you promptly.